MeSH term
Frequency | Condition_Probility | *Adaptor Proteins, Signal Transducing | 14 | 1.0 |
Amino Acid Sequence | 3 | 0.0 |
Animals | 15 | 0.0 |
COS Cells | 3 | 0.0 |
Humans | 32 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 4 | 0.0 |
Molecular Sequence Data | 4 | 0.0 |
Phosphorylation | 8 | 0.0 |
Point Mutation | 2 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 4 | 1.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 20 | 0.0 |
Signal Transduction | 4 | 0.0 |
Tyrosine/metabolism | 3 | 0.0 |
src Homology Domains | 7 | 1.0 |
Prognosis | 3 | 0.0 |
Cell Division/drug effects | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Comparative Study | 5 | 0.0 |
Female | 12 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Male | 11 | 0.0 |
Cell Division | 3 | 0.0 |
Cell Survival | 2 | 0.0 |
Mice | 8 | 0.0 |
Protein-Tyrosine Kinase/*physiology | 2 | 1.0 |
Proto-Oncogene Proteins/*physiology | 2 | 0.0 |
Transfection | 6 | 0.0 |
Carrier Proteins/metabolism | 3 | 0.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
*Neoplasm Proteins | 2 | 0.0 |
PC12 Cells | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 3 | 0.0 |
Rats | 4 | 0.0 |
*Receptor, trkA | 2 | 16.0 |
Tyrosine/*metabolism | 2 | 0.0 |
Amino Acid Substitution | 3 | 0.0 |
Cells, Cultured | 5 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
Ireland | 2 | 3.0 |
English Abstract | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Jurkat Cells | 2 | 0.0 |
Phospholipase C/metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 4 | 0.0 |
Aged | 4 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Blood Gas Monitoring, Transcutaneous | 2 | 40.0 |
Forefoot, Human/blood supply | 2 | 100.0 |
Middle Aged | 6 | 0.0 |
Skin/*blood supply | 3 | 8.0 |
Binding Sites | 2 | 0.0 |
Protein Binding | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 6 | 0.0 |
Adult | 5 | 0.0 |
Reference Values | 3 | 0.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Mutation | 4 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Proto-Oncogene Proteins/metabolism/*physiology | 2 | 4.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Time Factors | 2 | 0.0 |
Base Sequence | 2 | 0.0 |
Cell Line | 4 | 0.0 |
Carcinoma, Small Cell/drug therapy/*radiotherapy | 2 | 100.0 |
Combined Modality Therapy | 2 | 0.0 |
Lung Neoplasms/drug therapy/*radiotherapy | 2 | 66.0 |
Models, Biological | 2 | 0.0 |
*Abortion, Induced | 2 | 9.0 |
Pregnancy | 2 | 0.0 |
Phosphoproteins/*metabolism | 2 | 0.0 |
